|
EMA to Revise Multiplicity Points-to-Consider Guideline
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) is seeking public input as it works to update its points-to-consider document on multiplicity issues in clinical trials.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives